340B Compliance Insights: Expert Guidance for Healthcare Organizations

31 Aug Building a WAC Spend Recapture Workflow for Your 340B Program

Posted at 9:00 AM in Blog by Scott Ponaman

Every covered entity running a replenishment model buys some drugs at wholesale acquisition cost that should have been replaced at 340B pricing. Not because anyone did anything wrong, but because an eligible dispense did not accumulate, a mapping was missing, or a package never triggered....

Read More

26 Aug How to Evaluate 340B Consulting Firms and Audit Companies

Posted at 9:00 AM in Blog by Scott Ponaman

Most covered entities run this selection once every few years, which means the process is rarely practiced and the criteria are usually invented under time pressure. We sit on the other side of it constantly, and the pattern is consistent. Entities compare firms on price...

Read More

24 Aug When to Hire a 340B Program Consultant and What They Deliver

Posted at 9:00 AM in Blog by Scott Ponaman

Nobody hires a 340B program consultant because things are calm. They call when something changed and the program did not change with it. A merger. A new service line. A TPA switch. A finding. Or the slower version, where the program grew from four sites...

Read More

17 Aug 340B Audit Findings, Severity, and Remediation

Posted at 9:00 AM in Blog by Scott Ponaman

An audit letter is not the moment your program is judged. It is the moment your last three years of record keeping gets read back to you. Covered entities that come through well are not the ones with perfect programs. They are the ones who...

Read More

10 Aug What a 340B Compliance Partner Should Be Accountable For

Posted at 9:00 AM in Blog by Scott Ponaman

Covered entities bring in compliance partners for a reasonable reason. The work is continuous, the expertise is specialized, and internal teams are already stretched. What goes wrong is not the decision to bring someone in. It is a scope that never says out loud who...

Read More

03 Aug 340B Program Management Best Practices for Covered Entities

Posted at 9:00 AM in Blog by Scott Ponaman

A 340B program rarely fails all at once. It drifts. A child site opens and nobody updates the registration record. A state changes how it handles Medicaid managed care and the carve decision goes stale. An EHR upgrade quietly changes how dispenses are captured. Each...

Read More

28 Jul How Community Health Centers Protect 340B Savings When HRSA Comes Knocking

Posted at 3:54 AM in Blog by Scott Ponaman

The 340B drug pricing program delivers substantial savings to covered entities serving underserved patient populations. Savings that directly fund care for the patients who need it most. But those savings only stay protected when the compliance infrastructure around the program is built to withstand HRSA...

Read More

21 Jul Why 340B Compliance Feels Harder Than It Should. And What’s Actually Driving It

Posted at 4:01 AM in Blog by Scott Ponaman

Managing a 340B program isn't difficult because the rules are ambiguous. It's difficult because the rules are clear, the stakes are significant, and the organizational infrastructure most covered entities have built around the program was never designed to carry that weight. The compliance burden lives...

Read More

14 Jul The 2026 State of 340B Compliance: What’s Working, What Isn’t, and Where the Gaps Are Widening

Posted at 2:28 AM in Blog by Scott Ponaman

340B compliance in 2026 demands more than enrollment and policy documentation. Covered entities must maintain real-time oversight of patient eligibility, contract pharmacy arrangements, and audit-ready documentation. All under intensified HRSA scrutiny. Organizations treating compliance as a periodic exercise rather than a continuous operational function are...

Read More

07 Jul When to Act and When to Wait: Timing Decisions in 340B Compliance That Determine Audit Outcomes

Posted at 2:21 AM in Blog by Scott Ponaman

Timing in 340B compliance isn't about how fast you move. It's about whether you're moving on the right issue at the right moment. Programs that overreact to every regulatory update exhaust their teams on non-issues. Programs that delay on known internal gaps hand HRSA the...

Read More